Cargando…
Tumour microenvironment-responsive lipoic acid nanoparticles for targeted delivery of docetaxel to lung cancer
In the present study, we developed a novel type of reduction-sensitive nanoparticles (NPs) for docetaxel (DTX) delivery based on cross-linked lipoic acid NPs (LANPs). The physicochemical properties, cellular uptake and in vitro cytotoxicity of DTX loaded LANPs (DTX-LANPs) on A549 cells were investig...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5090365/ https://www.ncbi.nlm.nih.gov/pubmed/27805051 http://dx.doi.org/10.1038/srep36281 |
_version_ | 1782464392493793280 |
---|---|
author | Gu, Fenfen Hu, Chuling Tai, Zhongguang Yao, Chong Tian, Jing Zhang, Lijuan Xia, Qingming Gong, Chunai Gao, Yuan Gao, Shen |
author_facet | Gu, Fenfen Hu, Chuling Tai, Zhongguang Yao, Chong Tian, Jing Zhang, Lijuan Xia, Qingming Gong, Chunai Gao, Yuan Gao, Shen |
author_sort | Gu, Fenfen |
collection | PubMed |
description | In the present study, we developed a novel type of reduction-sensitive nanoparticles (NPs) for docetaxel (DTX) delivery based on cross-linked lipoic acid NPs (LANPs). The physicochemical properties, cellular uptake and in vitro cytotoxicity of DTX loaded LANPs (DTX-LANPs) on A549 cells were investigated. Furthermore, the in vivo distribution and in vivo efficacy of DTX-LANPs was evaluated. The results showed that DTX-LANPs had a particle size of 110 nm and a negative zeta potential of −35 mv with excellent colloidal stability. LANPs efficiently encapsulated DTX with a high drug loading of 4.51% ± 0.49% and showed remarkable reduction-sensitive drug release in vitro. Cellular uptake experiments demonstrated that LANPs significantly increased intracellular DTX uptake by about 10 fold as compared with free DTX. The cytotoxicity of DTX-LANPs showed significantly higher potency in inhibiting A549 cell growth than free DTX, while blank LANPs had a good biocompatibility. In addition, in vivo experiments demonstrated that DTX-LANPs could enhance tumour targeting and anti-tumour efficacy with low systemic toxicity. In conclusion, LANPs may prove to be a potential tumour microenvironment-responsive delivery system for cancer treatment, with the potential for commercialization due to the simple component, controllable synthesis, stability and economy. |
format | Online Article Text |
id | pubmed-5090365 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-50903652016-11-08 Tumour microenvironment-responsive lipoic acid nanoparticles for targeted delivery of docetaxel to lung cancer Gu, Fenfen Hu, Chuling Tai, Zhongguang Yao, Chong Tian, Jing Zhang, Lijuan Xia, Qingming Gong, Chunai Gao, Yuan Gao, Shen Sci Rep Article In the present study, we developed a novel type of reduction-sensitive nanoparticles (NPs) for docetaxel (DTX) delivery based on cross-linked lipoic acid NPs (LANPs). The physicochemical properties, cellular uptake and in vitro cytotoxicity of DTX loaded LANPs (DTX-LANPs) on A549 cells were investigated. Furthermore, the in vivo distribution and in vivo efficacy of DTX-LANPs was evaluated. The results showed that DTX-LANPs had a particle size of 110 nm and a negative zeta potential of −35 mv with excellent colloidal stability. LANPs efficiently encapsulated DTX with a high drug loading of 4.51% ± 0.49% and showed remarkable reduction-sensitive drug release in vitro. Cellular uptake experiments demonstrated that LANPs significantly increased intracellular DTX uptake by about 10 fold as compared with free DTX. The cytotoxicity of DTX-LANPs showed significantly higher potency in inhibiting A549 cell growth than free DTX, while blank LANPs had a good biocompatibility. In addition, in vivo experiments demonstrated that DTX-LANPs could enhance tumour targeting and anti-tumour efficacy with low systemic toxicity. In conclusion, LANPs may prove to be a potential tumour microenvironment-responsive delivery system for cancer treatment, with the potential for commercialization due to the simple component, controllable synthesis, stability and economy. Nature Publishing Group 2016-11-02 /pmc/articles/PMC5090365/ /pubmed/27805051 http://dx.doi.org/10.1038/srep36281 Text en Copyright © 2016, The Author(s) http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Article Gu, Fenfen Hu, Chuling Tai, Zhongguang Yao, Chong Tian, Jing Zhang, Lijuan Xia, Qingming Gong, Chunai Gao, Yuan Gao, Shen Tumour microenvironment-responsive lipoic acid nanoparticles for targeted delivery of docetaxel to lung cancer |
title | Tumour microenvironment-responsive lipoic acid nanoparticles for targeted delivery of docetaxel to lung cancer |
title_full | Tumour microenvironment-responsive lipoic acid nanoparticles for targeted delivery of docetaxel to lung cancer |
title_fullStr | Tumour microenvironment-responsive lipoic acid nanoparticles for targeted delivery of docetaxel to lung cancer |
title_full_unstemmed | Tumour microenvironment-responsive lipoic acid nanoparticles for targeted delivery of docetaxel to lung cancer |
title_short | Tumour microenvironment-responsive lipoic acid nanoparticles for targeted delivery of docetaxel to lung cancer |
title_sort | tumour microenvironment-responsive lipoic acid nanoparticles for targeted delivery of docetaxel to lung cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5090365/ https://www.ncbi.nlm.nih.gov/pubmed/27805051 http://dx.doi.org/10.1038/srep36281 |
work_keys_str_mv | AT gufenfen tumourmicroenvironmentresponsivelipoicacidnanoparticlesfortargeteddeliveryofdocetaxeltolungcancer AT huchuling tumourmicroenvironmentresponsivelipoicacidnanoparticlesfortargeteddeliveryofdocetaxeltolungcancer AT taizhongguang tumourmicroenvironmentresponsivelipoicacidnanoparticlesfortargeteddeliveryofdocetaxeltolungcancer AT yaochong tumourmicroenvironmentresponsivelipoicacidnanoparticlesfortargeteddeliveryofdocetaxeltolungcancer AT tianjing tumourmicroenvironmentresponsivelipoicacidnanoparticlesfortargeteddeliveryofdocetaxeltolungcancer AT zhanglijuan tumourmicroenvironmentresponsivelipoicacidnanoparticlesfortargeteddeliveryofdocetaxeltolungcancer AT xiaqingming tumourmicroenvironmentresponsivelipoicacidnanoparticlesfortargeteddeliveryofdocetaxeltolungcancer AT gongchunai tumourmicroenvironmentresponsivelipoicacidnanoparticlesfortargeteddeliveryofdocetaxeltolungcancer AT gaoyuan tumourmicroenvironmentresponsivelipoicacidnanoparticlesfortargeteddeliveryofdocetaxeltolungcancer AT gaoshen tumourmicroenvironmentresponsivelipoicacidnanoparticlesfortargeteddeliveryofdocetaxeltolungcancer |